MicuRx Of China Chooses First Antibiotic For Development
This article was originally published in PharmAsia News
Executive Summary
China's MicuRx Pharmaceuticals says it plans to conduct its first development effort on its MRX-I molecule to fight bacteria, including staphylococcus aureas, that are resistant to several drugs. The firm is readying the drug for preclinical trials while it expands its Chinese operations to increase its capacity to develop the medicine and other drugs in its pipeline. MicuRx plans another generation of antimicrobial products the expanded facilities would be designed to handle. Shengyu Yuan, MicuRx CEO, said the company has discovered several multiple-drug leads, and said MRX-I was a promising compound it expects to be superior to many top-selling antibiotics. (Click here for more